ABSTRACT
300?10~(9)/L. Results:One hundred and six patients were enrolled into this study. Of the 106 patients, 100 patients completed the study and were evaluable for efficacy. The median nadir of platelet was 49(5-76)?10~(9)/L in the control cycle and 69(6-221)?10~(9)/L in the study cycle. Median durations of PLT≤75?10~(9)/L, ≤50?10~(9)/L, and ≤20?10~(9)/L were 7 (0-26), 2 (0-20), and 0 (0-9) days in control cycle versus 3.5 (0-28) (P0.05) days in study cycle, respectively. The median duration of platelet recovery to 80?10~(9)/L was 5 (1-18) days in control cycle versus 2(0-28) days in study cycle (P
ABSTRACT
Mucosa-associated lymphoid tissue lymphomas are a distinct subgroup of non-Hodgin's lymphoma with a particular clinicopathologic behavior.It is the most common type of extranodal low-grade B cell lymphoma.This type of lymphoma tends to appear in patients with a history of autoimmune disease or chronic inflammatory disorders.These indolent lesions usually remain localized for long periods and often respond to local therapy.The most common site of MALT lymphoma is the stomach.This article reviews clinical features and management of MALT lymphoma,emphasizing on gastric MALT lymphoma.
ABSTRACT
Multidrug resistance (MDR) is the most common cause in the failure of cancer chemotherapy. Drug transporters play an important role in multidrug resistance in cancer. Activation of drug pumps which belong to ATP-binding cassette (ABC) transporters leads to the efflux of drug via cell membrane.Three subgroups of ABC transporters are involved in the transport of cytotoxic drugs.These transporters include ABCB subgroup,ABCC subgroup and ABCG subgroup. In this review,the author discussed the recent research advances in the ABC transporters associated with MDR.
ABSTRACT
Metastatic colorectal cancer is a major cause of cancer-related mortality. Surgical resection of all known metastatic disease can be curative in selected patients. The majority of patients,however,require systemic chemotherapy as optimal palliative treatment for their disease. For years,effective treatment for advanced colorectal cancer was limited to fluorouracil. In the 1990s,two additional agents,irinotecan and oxaliplatin,were found to have activity against advanced colorectal cancer. Recently,new molecular targeted agents,bevacizumab and cetuximab,were for the first time demonstrated efficacy. Herein,we review recent developments in treatment for metastatic colorectal cancer and implication for optimal treatment in these patients.